AiCuris Logo

Home  |  Contact  |  Imprint  |  Sitemap  |  Privacy notice  

cekom
  • Home
  • About AiCuris
    • Company Profile
    • Management Team
      • Holger Zimmermann
      • Holger Schmoll
      • Alexander Birkmann
      • Helmut Buschmann
      • Manickam Rangaraju
      • Silvia Riffel-Friedrich
    • Scientific Advisory Board
      • Helga Rübsamen-Schaeff
      • Mark Wilcox
      • Per Ljungman
    • Memberships
  • Research & Development
    • Strategy
    • R&D Pipeline
    • Bacteriology
      • Resistance
      • Projects
      • Scientific Publications
    • Virology
      • Indications & Medical Need
      • Projects
        • HCMV - Letermovir
        • HSV - Pritelivir (AIC316)
        • HBV - AIC649
      • Scientific Publications
    • Congress calendar
    • Research Tools & Services
  • Partnering & Licensing
    • AiCuris & Partnering
    • Partnering Opportunities
      • Autoimmunity treatment
      • Innovation for Hepatitis B
    • In-Licensing & Collaborations
    • Congress calendar
  • News & Media
    • Press releases
      • - 2018
      • - 2017
      • - 2016
      • - 2015
      • - 2014
      • - 2013
      • - 2012
      • - 2011 and before
    • Media
    • Services for Press
    • Deutscher Zukunftspreis - 2018 Award Winners
    • Press Kit Pressekonferenz MSD / AiCuris 22. Februar 2018
    • EFPIA Disclosure Code
  • Career
    • Join AiCuris
    • Employee Benefits
    • Job Opportunities
    • Privacy Notice for applicants
  • Contact
    • Directions
  • Press releases
    • - 2018
    • - 2017
    • - 2016
    • - 2015
    • - 2014
    • - 2013
    • - 2012
    • - 2011 and before
  • Media
  • Services for Press
  • Deutscher Zukunftspreis - 2018 Award Winners
  • Press Kit Pressekonferenz MSD / AiCuris 22. Februar 2018
  • EFPIA Disclosure Code

Press Kit Pressekonferenz MSD / AiCuris 22. Februar 2018

 

Hier finden Sie alle Dokumente unserer Pressekonferenz
MSD / AiCuris 22. Februar 2018:

 

2018-02-23 AiCuris‘ Lizenznehmer MSD bringt das Medikament PREVYMIS®(Letermovir) in Deutschland auf den Markt

 

2018-02-23 AiCuris’ Licensee MSD launches PREVYMIS™ (letermovir) in Germany

 

 

Pressemitteilungen zu Letermovir:

2018-01-31_AiCuris_PM_Letermovir_EU_Zulassung

2017-11-13 PR AiCuris_PM_Letermovir_CHMP EU

 

2017-11-09 PR AiCuris_PM_Letermovir_Approval

2016-10-19 PR AiCuris_Pressemitteilung_MSD_Letermovir_PH_3

2014-07-24 PR Merck News release 07 24 14 -Phase 3 Study of  MK-8228

2013-12-05 PR  STEP Award

2013-05-08 PR  Breakthrough Alliance Award

2012-10-15 PR AICURIS AND MERCK ENTER EXCLUSIVE WORLDWIDE

2012-02-14 PR AiCuris Medikament Letermovir AIC246 Wirksamkeits-Endpunkte in Phase 2

2010-10-21 PR HCMV eIND D

2009-09-15 PR Phase II D

 

Vorstellung der Redner
o Dr. Holger Zimmermann
o Prof. Dr. Helga Rübsamen-Schaeff 
o Dr. Dr. med Kristian Löbner
o Dr. Thomas Strüngmann

PDF CVs

 

  • About AiCuris
  • Company Profile
  • Management
  • Contact
  • Directions
  • Research & Development
  • Strategy
  • R&D Pipeline
  • Bacteriology
  • Virology
  • Partnering & Licensing
  • AiCuris & Partnering
  • Partnering Opportunities
  • In-Licensing & Collaborations
  • News & Media
  • Press releases
  • Services for Press
  • Career
  • Join AiCuris
  • Job Opportunities
  • Contact
  • Home
  • Contact
  • Imprint
  • Sitemap